Advertisement

Topics

Rocket Pharma partners with Stanford University to advance FA and PKD gene therapy research

05:44 EDT 17 May 2018 | News-Medical.net

Rocket Pharmaceuticals, Inc., a leading U.S.-based multi-platform gene therapy company, and the Stanford University School of Medicine today announced a strategic collaboration to support the advancement of Fanconi Anemia and Pyruvate Kinase Deficiency gene therapy research.

Original Article: Rocket Pharma partners with Stanford University to advance FA and PKD gene therapy research

NEXT ARTICLE

More From BioPortfolio on "Rocket Pharma partners with Stanford University to advance FA and PKD gene therapy research"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...